...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Nephrology >Acute kidney injury: Acetylcysteine does not prevent contrast-induced acute kidney injury.
【24h】

Acute kidney injury: Acetylcysteine does not prevent contrast-induced acute kidney injury.

机译：急性肾损伤：乙酰半胱氨酸不能预防造影剂引起的急性肾损伤。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Alarge, randomized, placebo-controlled trial has found that kacetylcysteine does not reduce the risk of contrast-induced acute kidney injury (AKI) in high-risk patients undergoing angiography.Acetylcysteine has been assessed for the prevention of contrast-induced AKI in a number of trials as this drug is thought to reduce direct oxidative stress and improve renal hemo dynamics following the use of contrast medium. However, current guidelines disagree on whether this intervention should be recommended for patients at high risk and clinicians remain unsure about the effectiveness of acetylcysteine. "Over 40 acetylcysteine studies have been completed in the past 10 years and reached inconsistent results," says Otavio Berwanger on behalf of the Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT) Investigators.
机译：一项大型，随机，安慰剂对照试验发现，乙酰基半胱氨酸不能降低造影剂高危患者造影剂引起的急性肾损伤（AKI）的风险。乙酰半胱氨酸已被评估用于预防造影剂引起的AKI。试验被认为是该药物在使用造影剂后可降低直接氧化应激并改善肾脏血液动力学。但是，目前的指南在是否应向高危患者推荐这种干预措施上存在分歧，临床医生仍不确定乙酰半胱氨酸的有效性。 Otavio Berwanger代表乙酰半胱氨酸进行造影剂肾病研究（ACT）研究者说：“在过去10年中，已经完成了40多个乙酰半胱氨酸研究，但结果不一致。”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号